BTG signs development agreement with Impella:
This article was originally published in Clinica
UK transfer technology company BTG has signed a non-exclusive agreement for its liver assist technology with German start-up Impella Cardiotechnik. The Aachen-based company plans to develop the technology for the treatment of portal hypertension, which is associated with cirrhosis of the liver. The technology will comprise a micropump which will be implanted adjacent to the liver in the hepatic portal vein and is designed to increase blood flow through the liver. The liver assist concept was developed by Nagy Habib of the Imperial College School of Medicine, Hammersmith hospital, London.